Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 184.82

-2.0%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mudcat who wrote (16990)	3/9/1998 8:59:00 PM
From: Henry Niman	Read Replies (1) of 32384

There is nothing new in the press release, except for the extension (and European sales?). LGND is not buying some stock and selling it to LLY for a 20% profit. They are either issuing stock to increase LLY's equity position or they are licensing a drug from LLY. If they take the cash, they also get a higher royalty rate on the rexinoid of their choice. Thus, the cash part increases LGND's bank account in two ways (cash and royalty). If they choose the drug, the $20 million paid to LLY would be from the profits, which would be higher than $20 million. I think that the extension is to determine if the net will be positive by 1999. I suspect that the initial cost of setting up the sale of the drug may be higher and/or more complicated than LGND initially expected. I also don't recall Europe being mentioned previously for the new compound (although LGND is seeking European approval for the in-house drugs).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next